FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer - Related Studies

FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (TOSCA)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2009 by Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente.
Recruitment status was Recruiting

Study NCT00646607 Information provided by Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

First Received on March 17, 2008. Last Updated on December 14, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Colon Cancer

Additional conditions recognized in this trial

Colonic Neoplasms

More general conditions related to this trial

Additional drug interventions recognized in this trial

Bevacizumab
Fluorouracil
Leucovorin
Levoleucovorin
Oxaliplatin

More general drug interventions related to this trial

Sponsors listed in this trial